In a Wall Street Journal opinion piece, James Mullen, CEO of Biogen Idec and chairman of BIO, recounts the successes of the biotech industry while warning that "a witch's brew of initiatives" currently proposed by US lawmakers could have a serious impact on the field.
Get the full story
This story is free
for registered users
Registering provides access to this and other free content.
Register now.Already have an account?
Login Now.